Skip to main content

Highlights

  1. 1
    Cancer discovery · 2024
    PMID: 38969342PMCID: PMC11984259DOISenior author11 citations

Publications

24 publications

Active

6 grants
  • Co-I
    Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancer
    National Cancer Institute · 2025–2030
    R01CA297829-01
  • KP
    Defining Evolution of Prostate Cancer Metastasis Under Therapeutic Pressure Using Recordable Barcode
    Prostate Cancer Foundation · 2025–2028
    25YOUN26
  • PI
    "Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis"
    National Cancer Institute · 2023–2028
    R01CA272466-04
  • KP
    Determining Metastatic Drivers of Pten/p53-Loss-Driven Prostate Cancer Using Evolving DNA Barcodes
    U.S. Department of Defense · 2022–2026
    W81XWH-22-1-0068
  • PI
    Defining Evolutionary Trajectories Driving Prostate Cancer Metastases
    American Cancer Society · 2021–2026
    RSG-21-057-01-SCM
  • PI
    Determining and Targeting Evolutionary Trajectories Driving Bladder Cancer
    Starr Cancer Consortium · 2023–2025
    SCC I16-0060
Completed grants (2)
  • KP
    Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
    National Cancer Institute · 2017–2023
    P50CA211024-01A1
  • PI
    Addgene 705286
    Addgene, Inc. · 2022–2023
    Addgene 705286

News mentions

External relationships

Proprietary Interest

University of Bristol